DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award

Defense Health Agency Contracting Activity - DHACAAmount not specifiedDue Sep 30, 2026

Researchers Schools & universities Broad eligibility

Deadline: Sep 30, 2026
Posted: May 4, 2026
Award amount: Amount not specified
Focus areas: Science and Technology and other Research and Development

Don’t miss this deadline

We’ll email you before Sep 30, 2026 so you have time to apply.

In plain English

This Department of War (Defense Health Agency) ALS Research Program Pilot Clinical Trial Award supports rapid implementation of phase 1 to small-scale phase 2 trials affecting ALS treatment or management. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Applications must address biomarker-driven interventions or clinical care, incorporate community collaboration, and include a regulatory strategy and transition plan. No specific award amount is stated.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

About this grant

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Science and Technology and other Research and Development — soonest deadline first.

Also listed under Defense Health Agency Contracting Activity - DHACA and Science & Research Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.